Company news

Nuvectis Pharma, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Nuvectis Pharma Announces Encouraging Preliminary Data from the NXP800 Phase 1b Clinical Trial in Platinum-Resistant ARID1a-Mutated Ovarian Cancer

March 13, 2024

Nuvectis Pharma, Inc. Reports Fiscal Year 2023 Financial Results and Business Highlights

March 4, 2024

Nuvectis Pharma Announces Participation at Upcoming Investor Conferences

February 8, 2024

Nuvectis Pharma to Present at the 42nd Annual J.P. Morgan Healthcare Conference

January 2, 2024

Nuvectis Pharma, Inc. Announces a Collaboration with Mayo Clinic to Evaluate NXP800 in an Investigator-Sponsored Clinical Trial in Cholangiocarcinoma

December 17, 2023

Nuvectis Pharma, Inc. Reports Third Quarter 2023 Financial Results and Business Highlights

November 7, 2023

Nuvectis Pharma Announces Upcoming Poster Presentation for NXP800 at the 2023 AACR Special Conference on Endometrial Cancer

October 23, 2023

Nuvectis Pharma Announces Updated Date and Time for the 2023 Cantor Global Healthcare Conference Corporate Presentation

September 24, 2023

Nuvectis Pharma Announces Upcoming Presentations for NXP800 and NXP900

September 20, 2023

Nuvectis Pharma Announces Initiation of the NXP900 Phase 1a Clinical Trial

September 11, 2023

Nuvectis Pharma to Host KOL Event to Discuss Its Two Precision Medicine Clinical-Stage Drug Candidates, NXP800 and NXP900

September 5, 2023

Nuvectis Pharma Announces Orphan Drug Designation Granted by the FDA to NXP800 for the Treatment of Cholangiocarcinoma

August 16, 2023

Nuvectis Pharma, Inc. Reports Second Quarter 2023 Financial Results and Business Highlights

August 8, 2023

Nuvectis Pharma Set to Join the Russell 2000® and Russell 3000® Indexes

June 19, 2023

Nuvectis Pharma Announces FDA Clearance of NXP900 IND

May 14, 2023

Nuvectis Pharma, Inc. Reports First Quarter 2023 Financial Results and Business Highlights

May 9, 2023

Nuvectis Pharma Recaps Poster Presentation Highlights for NXP800's Activity in Cholangiocarcinoma PDX Models at the 2023 American Association for Cancer Research (“AACR”) Annual Meeting

April 17, 2023

Nuvectis Pharma Announces Initiation of the Phase 1b Study for NXP800 in Platinum-Resistant, ARID1a-Mutated Ovarian Carcinoma

April 9, 2023

Nuvectis Pharma Announces Upcoming Presentations at the 2023 American Association for Cancer Research Meeting

March 16, 2023

Nuvectis Pharma to Participate in a Fireside Chat at the 35th Annual Roth Conference

March 9, 2023

Nuvectis Pharma, Inc. Reports Fiscal Year 2022 Financial Results and Business Highlights

March 6, 2023

Nuvectis Pharma Recaps Poster Presentation Highlights for NXP800 at the 2023 ESMO Gynecological Cancers Congress

February 22, 2023

Nuvectis Pharma Announces a Publication in The Journal of Experimental Medicine for NXP900 in an In-Vivo Model of Metastatic Castration Resistant Prostate Cancer (“mCRPC”) with Acquired Resistance to Enzalutamide, the Active Ingredient in Xtandi®

February 8, 2023

Nuvectis Pharma Announces Collaboration with ENGOT and GOG Foundation to Conduct the NXP800 Phase 1b Clinical Trial in ARID1A-Mutated Ovarian Carcinoma in Europe and in the United States

January 3, 2023

FDA Grants Fast Track Designation to Nuvectis Pharma's NXP800 for the Treatment of Platinum-Resistant, ARID1A-Mutated Ovarian Carcinoma

November 30, 2022

Nuvectis Pharma, Inc. Reports Third Quarter 2022 Financial Results and Business Highlights

November 7, 2022

Nuvectis Phrama Announces Two Upcoming Poster Presentations at the 34th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

October 17, 2022

Nuvectis Pharma, Inc. to Present at the Roth Inaugural Healthcare Opportunities Conference

October 2, 2022

Nuvectis Pharma Announces Formation of a Scientific Advisory Board

September 27, 2022

Nuvectis Pharma Announces Positive Data for NXP800 in a Preclinical Model of ARID1a-Mutated Gastric Carcinoma

September 12, 2022

Nuvectis Pharma, Inc. to Present at Upcoming Investment Conferences

September 6, 2022

Nuvectis Pharma, Inc. Reports Second Quarter 2022 Financial Results and Business Highlights

August 4, 2022

Nuvectis Pharma, Inc. Announces Approximately $15.9 Million Private Placement

July 26, 2022

Nuvectis Pharma Announces FDA Clearance of IND for NXP800

June 20, 2022

Nuvectis Pharma Announces Positive Data for NXP900 in a Preclinical Model of Group 4 Medulloblastoma, A Type of Brain Cancer That Affects Predominantly Pediatric Patients

June 12, 2022

Nuvectis Pharma to Present in the H.C. Wainwright Global Investment Conference

May 19, 2022

Nuvectis Pharma, Inc. Reports First Quarter 2022 Financial Results and Business Highlights

May 9, 2022

Nuvectis Pharma Recaps Poster Presentation Highlights for NXP900 at the 2022 American Association for Cancer Research (AACR) Conference

April 12, 2022

Nuvectis Pharma Recaps Oral Presentation Highlights for NXP800 at the 2022 American Association for Cancer Research (AACR) Conference

April 10, 2022

Nuvectis Pharma, Inc. Reports Fiscal Year 2021 Financial Results and Business Highlights

March 21, 2022

Nuvectis Announces Upcoming Oral and Poster Presentations at the 2022 American Association for Cancer Research Meeting

March 9, 2022

Update - Nuvectis Pharma to Participate in a Fireside Chat at the 34th Annual Roth Conference

March 8, 2022

Nuvectis Announces Positive Data for NXP900 in Triple Negative Breast Cancer Preclinical Models with an Integrin-Linked Kinase (ILK) Loss

February 21, 2022

Nuvectis Pharma Announces Closing of $16,000,000 Upsized Initial Public Offering of Common Stock

February 7, 2022

Nuvectis Pharma, Inc. Announces Pricing of $16,000,000 Upsized Initial Public Offering of Common Stock

February 3, 2022

← Newer news releases

Calls

Decks

The 5 newest of 6 decks. Every deck is listed under its year.